相似文献
1
Inhibitory effect of rivaroxaban on protease-activated receptor-2 in circulating neutrophils among patients with atrial fibrillation.
Int J Cardiol Heart Vasc. 2024 Mar 20;52:101387. doi: 10.1016/j.ijcha.2024.101387. eCollection 2024 Jun.
2
Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study.
BMJ. 2015 Apr 24;350:h1857. doi: 10.1136/bmj.h1857.
3
Comparative Safety and Effectiveness of Oral Anticoagulants in Nonvalvular Atrial Fibrillation: The NAXOS Study.
Stroke. 2020 Jul;51(7):2066-2075. doi: 10.1161/STROKEAHA.120.028825. Epub 2020 Jun 16.
4
Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data.
Lancet Haematol. 2019 Jul;6(7):e359-e365. doi: 10.1016/S2352-3026(19)30086-9. Epub 2019 May 24.
5
Nonvalvular atrial fibrillation patients anticoagulated with rivaroxaban compared with warfarin exhibit reduced circulating extracellular vesicles with attenuated pro-inflammatory protein signatures.
J Thromb Haemost. 2021 Oct;19(10):2583-2595. doi: 10.1111/jth.15434. Epub 2021 Jul 16.
6
Direct Oral Anticoagulants Versus Vitamin K Antagonists in Real-life Patients With Atrial Fibrillation. A Systematic Review and Meta-analysis.
Rev Esp Cardiol (Engl Ed). 2019 Apr;72(4):305-316. doi: 10.1016/j.rec.2018.03.009. Epub 2018 Mar 30.
7
Comparison of the cost-effectiveness of new oral anticoagulants for the prevention of stroke and systemic embolism in atrial fibrillation in a UK setting.
Clin Ther. 2014 Dec 1;36(12):2015-2028.e2. doi: 10.1016/j.clinthera.2014.09.015. Epub 2014 Oct 23.
8
Sex-Specific Comparative Effectiveness of Oral Anticoagulants in Elderly Patients With Newly Diagnosed Atrial Fibrillation.
Circ Cardiovasc Qual Outcomes. 2017 Apr;10(4). doi: 10.1161/CIRCOUTCOMES.116.003418.
9
Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation.
J Am Heart Assoc. 2018 Apr 13;7(8):e008643. doi: 10.1161/JAHA.118.008643.
10
Effectiveness and safety of direct oral anticoagulants compared to warfarin in treatment naïve non-valvular atrial fibrillation patients in the US Department of defense population.
BMC Cardiovasc Disord. 2019 Jun 13;19(1):142. doi: 10.1186/s12872-019-1116-1.
本文引用的文献
1
Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease.
N Engl J Med. 2019 Sep 19;381(12):1103-1113. doi: 10.1056/NEJMoa1904143. Epub 2019 Sep 2.
2
Rivaroxaban, a Direct Factor Xa Inhibitor, Ameliorates Hypertensive Renal Damage Through Inhibition of the Inflammatory Response Mediated by Protease-Activated Receptor Pathway.
J Am Heart Assoc. 2019 Apr 16;8(8):e012195. doi: 10.1161/JAHA.119.012195.
3
Rivaroxaban Suppresses the Progression of Ischemic Cardiomyopathy in a Murine Model of Diet-Induced Myocardial Infarction.
J Atheroscler Thromb. 2019 Oct 1;26(10):915-930. doi: 10.5551/jat.48405. Epub 2019 Mar 14.
4
Possible role of rivaroxaban in attenuating pressure-overload-induced atrial fibrosis and fibrillation.
J Cardiol. 2018 Mar;71(3):310-319. doi: 10.1016/j.jjcc.2017.08.007. Epub 2017 Oct 6.
5
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.
N Engl J Med. 2017 Oct 5;377(14):1319-1330. doi: 10.1056/NEJMoa1709118. Epub 2017 Aug 27.
6
Reduction of intracerebral hemorrhage by rivaroxaban after tPA thrombolysis is associated with downregulation of PAR-1 and PAR-2.
J Neurosci Res. 2017 Sep;95(9):1818-1828. doi: 10.1002/jnr.24013. Epub 2016 Dec 30.
7
Dabigatran enhances platelet reactivity and platelet thrombin receptor expression in patients with atrial fibrillation.
J Thromb Haemost. 2017 Mar;15(3):473-476. doi: 10.1111/jth.13595. Epub 2017 Feb 6.
8
Pleiotropic effects of factor Xa and thrombin: what to expect from novel anticoagulants.
Cardiovasc Res. 2014 Mar 1;101(3):344-51. doi: 10.1093/cvr/cvt343. Epub 2014 Jan 2.
9
Redox regulation of human protease-activated receptor-2 by activated factor X.
Free Radic Biol Med. 2011 Nov 1;51(9):1758-64. doi: 10.1016/j.freeradbiomed.2011.08.003. Epub 2011 Aug 12.
10
Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial.
Lancet. 2009 Jul 4;374(9683):29-38. doi: 10.1016/S0140-6736(09)60738-8. Epub 2009 Jun 17.
Zotero 插件
